Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

(2017) Nikhil C. Munshi et al.   JAMA Oncology

Progress and Paradigms in Multiple Myeloma

(2016) Kenneth C. Anderson   CLINICAL CANCER RESEARCH

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)

(2016) SABNA RAJEEV KRISHNAN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunomics: a 21st century approach to vaccine development for complex pathogens

(2016) KARINA P. DE SOUSA et al.   PARASITOLOGY

The Future of Myeloma Therapy: One Size Does Not Fit All

(2016) Paul G. Richardson   Journal of Oncology Practice

Treatment options for relapsed and refractory multiple myeloma

(2015) A. K. Nooka et al.   BLOOD

Promising therapies in multiple myeloma

(2015) G. Bianchi et al.   BLOOD

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy

(2015) S. Walz et al.   BLOOD

Pathogenesis beyond the cancer clone(s) in multiple myeloma

(2015) G. Bianchi et al.   BLOOD

Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses

(2015) Yasuharu Nishimura et al.   CANCER SCIENCE

High-Antibody-Producing Chinese Hamster Ovary Cells Up-Regulate Intracellular Protein Transport and Glutathione Synthesis

(2015) Camila A. Orellana et al.   JOURNAL OF PROTEOME RESEARCH

Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains

(2015) Junwei Shi et al.   NATURE BIOTECHNOLOGY

Integrative network modeling approaches to personalized cancer medicine

(2015) Brian A Kidd et al.   Personalized Medicine

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

(2015) Jahangir Abdi et al.   Oncotarget

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

The High Throughput Biomedicine Unit at the Institute for Molecular Medicine Finland: High Throughput Screening Meets Precision Medicine

(2014) Vilja Pietiainen et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

Monitoring M-Proteins in Patients with Multiple Myeloma Using Heavy-Chain Variable Region Clonotypic Peptides and LC–MS/MS

(2014) David R. Barnidge et al.   JOURNAL OF PROTEOME RESEARCH

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

(2014) H A F Stessman et al.   LEUKEMIA

Gene expression profile alone is inadequate in predicting complete response in multiple myeloma

(2014) S B Amin et al.   LEUKEMIA

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

(2014) L Melchor et al.   LEUKEMIA

A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients

(2014) J Bae et al.   LEUKEMIA

The role of P-glycoprotein in drug resistance in multiple myeloma

(2014) Joseph Abraham et al.   LEUKEMIA & LYMPHOMA

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Utilization of Translational Bioinformatics to Identify Novel Biomarkers of Bortezomib Resistance in Multiple Myeloma

(2014) Deanna J. Fall et al.   Journal of Cancer

An 'omics approach towards CHO cell engineering

(2013) Payel Datta et al.   BIOTECHNOLOGY AND BIOENGINEERING

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients

(2013) Willemijn Hobo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Zoom Zoom: Racing CARs for Multiple Myeloma

(2013) M. V. Maus et al.   CLINICAL CANCER RESEARCH

Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing

(2013) Luca Agnelli et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib

(2013) H A F Stessman et al.   LEUKEMIA

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

(2013) Joseph R. Mikhael et al.   MAYO CLINIC PROCEEDINGS

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

(2013) H. A. F. Stessman et al.   MOLECULAR CANCER THERAPEUTICS

Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization

(2013) Evan W Newell et al.   NATURE BIOTECHNOLOGY

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin

(2013) Bo Mu et al.   PLoS One

WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide

(2012) Yoshihiro Oka et al.   Anti-Cancer Agents in Medicinal Chemistry

Darwinian evolution and tiding clones in multiple myeloma

(2012) N. J. Bahlis   BLOOD

Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes

(2012) Rui Chen et al.   CELL

Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

(2012) J. Bae et al.   CLINICAL CANCER RESEARCH

Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma

(2012) P C Schuberth et al.   GENE THERAPY

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Omics and Drug Response

(2011) Urs A. Meyer et al.   Annual Review of Pharmacology and Toxicology

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

(2011) Y. X. Zhu et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders

(2011) Jooeun Bae et al.   BRITISH JOURNAL OF HAEMATOLOGY

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma

(2011) J Bae et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

BRAFMutations in Hairy-Cell Leukemia

(2011) Enrico Tiacci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma

(2010) A. P. Rapoport et al.   BLOOD

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909

(2010) Jürgen Kuball et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

(2010) J. Greiner et al.   HAEMATOLOGICA

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

(2010) J. Moreaux et al.   HAEMATOLOGICA

Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma

(2010) Johann Micallef et al.   Journal of Hematology & Oncology

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

(2010) M A Dimopoulos et al.   LEUKEMIA

Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone

(2010) Hong Chang et al.   LEUKEMIA & LYMPHOMA

Peptide-based immunotherapy for multiple myeloma: Current approaches

(2010) Fu-ling Zhou et al.   VACCINE

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Epidermal Growth Factor Receptor Variant III-Induced Glioma Invasion Is Mediated through Myristoylated Alanine-Rich Protein Kinase C Substrate Overexpression

(2009) J. Micallef et al.   CANCER RESEARCH

Microarray-Based Response Prediction in Esophageal Adenocarcinoma

(2009) M. Schauer et al.   CLINICAL CANCER RESEARCH

Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma

(2009) Ariel Anguiano et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition

(2009) J. R. St-Germain et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone

(2008) F. Zhan et al.   BLOOD

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome

(2008) Olivier Decaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Elucidation of potential bortezomib response markers in mutliple myeloma patients

(2008) Frank Y. Hsieh et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer

(2008) Koichi Nagasaki et al.   Breast Cancer